Scarica l'app Stockscreener
19.82
0.20%
-0.04
Dopo l'orario di chiusura:
20.00
0.18
+0.91%
Lb Pharmaceuticals Inc Borsa (LBRX) Ultime notizie
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Up 5.6%What's Next? - MarketBeat
LB Pharmaceuticals added to Russell 2000 and 3000 Indexes - MSN
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Lexicon publishes preclinical data validating ACSL5 as obesity target By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Inc (NASDAQ:LBRX) Expands Mental Health Pipeline - Kalkine Media
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Lexicon publishes preclinical data validating ACSL5 as obesity target - Investing.com
LB Pharmaceuticals Added to the Russell 2000 and Russell 3000 Indices - marketscreener.com
LB Pharmaceuticals (NASDAQ:LBRX) Trading Down 4.8%Here's Why - MarketBeat
LB Pharmaceuticals Added to Russell 2000, 3000 Indices - marketscreener.com
LB Pharmaceuticals to join Russell 2000 and Russell 3000 indices - Investing.com
LB Pharmaceuticals to join Russell 2000 and Russell 3000 indices By Investing.com - Investing.com South Africa
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices - marketscreener.com
LB Pharmaceuticals (NASDAQ:LBRX) Trading Up 6.2%Still a Buy? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week HighHere's What Happened - MarketBeat
LBRX: $300M IPO funds phase III schizophrenia and phase II bipolar depression trials, with 2027 data expected - TradingView
LB Pharmaceuticals Inc (LBRX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives $30.50 Average PT from Brokerages - Defense World
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Neuropsychiatric drug developer LB Pharma files for U.S. IPO - MSN
LB Pharmaceuticals Inc: Target Price Consensus and Analysts Recommendations | LBRX | US50180M1080 - MarketScreener
LB Pharmaceuticals Inc: Revenue and Earnings Analysts Forecasts Revisions | LBRX | US50180M1080 - MarketScreener
LB Pharmaceuticals Inc: Dividend historical data and projections - MarketScreener
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday - Benzinga
LB Pharmaceuticals Appoints New Chief Commercial Officer - MSN
LB Pharmaceuticals amends lease to expand New York office space By Investing.com - Investing.com Australia
LB Pharmaceuticals Expands Lease at One Penn Plaza - TipRanks
LB Pharmaceuticals amends lease to expand New York office space - Investing.com India
[8-K] LB PHARMACEUTICALS INC Reports Material Event | LBRX SEC FilingForm 8-K - Stock Titan
LB Pharmaceuticals appoints Kaya Pai Panandiker as chief commercial officer - Investing.com Nigeria
LB Pharmaceuticals names Kaya Pai Panandiker as CCO - The Pharma Letter
LB Pharmaceuticals appoints Kaya Pai Panandiker as chief commercial officer By Investing.com - Investing.com South Africa
LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer - The Manila Times
LB Pharmaceuticals, Inc Announces Appointment of Kaya Pai Panandiker as Chief Commercial Officer - MarketScreener
LB Pharmaceuticals - Nasdaq
LB Pharmaceuticals Reports Strong Q3 and Strategic Progress - TipRanks
LB Pharmaceuticals (NASDAQ:LBRX) Issues Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
LB Pharmaceuticals Inc.: Q3 Earnings Snapshot - theheraldreview.com
LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference - The Manila Times
LB Pharmaceuticals reports Q3 results, plans Phase 3 trial for LB-102 - Investing.com Nigeria
LB Pharmaceuticals reports Q3 results, plans Phase 3 trial for LB-102 By Investing.com - Investing.com South Africa
LBRX: IPO raised $327.8M; LB-102 advances with strong data; Q3 net loss narrows to $3.6M - TradingView
0.39%
1.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):